Spravato vs Ketamine: $10/Session vs $500 — Which Is Right for You? (2026)

If you're researching ketamine treatment for treatment-resistant depression, you'll quickly run into two options: IV ketamine infusions and Spravato (esketamine nasal spray). Clinics offer both. Psychiatrists recommend both. Insurance covers one of them and largely ignores the other. The clinical trial data on both is now extensive.

Yet most comparisons online get key facts wrong — outdated approval dates, inflated efficacy claims, incorrect insurance figures.

This guide uses only documented, verifiable data. No invented statistics.

Quick Reference: IV Ketamine vs. Spravato

	IV Ketamine	Spravato (Esketamine)
FDA approval (psychiatric)	None — off-label use	3 indications (TRD, MDD-SI, TRD monotherapy)
Administration	IV infusion, 40–60 min	Nasal spray, 2-hr in-office monitoring
Drug cost per dose	Under $10	$882–$1,663 (retail)
Uninsured session cost	$400–$800	$1,050–$2,000 (drug + monitoring)
Insurance coverage rate	~1.2% of plans (depression)	100% of 18 major commercial insurers
Manufacturer savings program	None	Yes — $10/session medication copay for eligible insured patients
REMS certification required	No	Yes
Response rate (clinical trials)	55.4% (ELEKT-D, NEJM 2023)	~50% at induction end (SUSTAIN-3)

FDA Approval Status: A Critical Difference

This is the most important structural difference between the two treatments — and the one with the largest downstream consequences for cost and insurance.

IV Racemic Ketamine

IV ketamine received FDA approval in 1970 as an anesthetic agent. That approval has never changed. Every psychiatric application — depression, PTSD, anxiety, suicidality — is off-label use. The FDA has not evaluated or endorsed IV ketamine for these conditions, even though the clinical evidence has become substantial.

"Off-label" does not mean unsafe or ineffective. Off-label prescribing is common and legal. But it does mean that insurance companies have grounds to deny coverage, and most exercise that right.

Spravato (Esketamine)

Spravato is the S-enantiomer of ketamine — a chemically related but distinct compound — and it has accumulated three separate FDA indications:

March 2019: Treatment-resistant depression (TRD) used alongside an oral antidepressant
August 2020: Major depressive disorder with acute suicidal ideation or behavior (MDD-SI)
January 2025: TRD as monotherapy — the first FDA-approved standalone treatment for TRD, requiring no concurrent oral antidepressant

The January 2025 monotherapy approval is significant. It removed a meaningful access barrier for patients who cannot tolerate oral antidepressants, and it further strengthened Spravato's insurance coverage position.

Spravato requires administration at a certified healthcare facility under the REMS (Risk Evaluation and Mitigation Strategy) program. You self-administer the nasal spray under supervision and remain monitored for at least two hours after each dose.

How They Differ Mechanistically

Both treatments exploit the same fundamental biology — NMDA receptor antagonism — but they are not identical.

IV racemic ketamine contains an equal mixture of two mirror-image molecules: R-ketamine and S-ketamine (esketamine). Research suggests the two enantiomers may have different activity profiles, with some data pointing to R-ketamine as having a longer-lasting antidepressant effect with fewer dissociative side effects — though this remains an active area of investigation.

Spravato contains only S-ketamine (esketamine). It's absorbed through the nasal mucosa rather than directly into the bloodstream, which affects both bioavailability and onset dynamics.

The administration routes also differ practically:

IV ketamine: Precise dosing, direct bloodstream delivery, 40–60 minute sessions, requires IV placement
Spravato: Self-administered nasal spray, 2-hour in-office monitoring required, variable absorption

Efficacy: What the Evidence Actually Shows

Head-to-Head: Mayo Clinic 2025 Meta-Analysis

The most direct comparison comes from a 2025 Mayo Clinic meta-analysis of 8 studies involving 978 patients. Conclusion: comparable efficacy between IV ketamine and esketamine, with a non-significant edge favoring IV ketamine. Neither outperformed the other by a clinically meaningful margin in this analysis.

IV Ketamine: The ELEKT-D Trial

The landmark ELEKT-D trial, published in NEJM in 2023 (N=403), compared IV ketamine directly against electroconvulsive therapy (ECT) in patients with treatment-resistant depression. Results:

Response rate: 55.4%
Remission rate: 38%
IV ketamine outperformed ECT in this comparison

ECT has historically been the gold standard for severe TRD. An IV ketamine response rate of 55.4% beating ECT — with substantially lower burden and side effect profile — was a landmark finding.

Spravato: The ESCAPE-TRD Trial

The ESCAPE-TRD trial, also published in NEJM in 2023 (N=676), compared Spravato plus standard-of-care against standard-of-care alone in TRD patients. Results:

Remission at week 8: 27.1% (Spravato) vs. 17.6% (control)
Remission at week 32: 55.0% (Spravato) vs. 37.0% (control)

The week-32 remission rate of 55.0% for Spravato is notably high, reflecting sustained benefit for patients who remain in the treatment protocol.

Long-Term Data: SUSTAIN-3

For durability, the SUSTAIN-3 study (~6.5 years of follow-up, 1,148 patients) provides the longest available dataset for esketamine. At induction end, approximately 50% of patients responded and 36.3% achieved remission. Long-term continuation in the study was associated with sustained benefit for many patients.

NNT: A Nuanced Picture

Number needed to treat (NNT) data reveals an important nuance about the timing of effect (Calder et al., Journal of Affective Disorders, 2024):

IV ketamine NNT: 3, measured over the 1-day to 1-week window
Esketamine NNT: 2 at 1 day (superior acute response), but 11 at 4 weeks

Esketamine produces a stronger acute response at 24 hours — NNT of 2 is exceptional. But IV ketamine's NNT of 3 holds up over the 1-day-to-1-week period, and the esketamine NNT of 11 at 4 weeks suggests its effects diminish more substantially over time compared to the acute peak.

Clinical implication: If rapid stabilization within 24 hours is the priority (e.g., acute suicidality), esketamine's acute NNT advantage may be relevant. For sustained response over weeks, the IV ketamine data appears more favorable based on NNT.

Cost Comparison: The Numbers

Cost is where the two treatments diverge most dramatically — and where the FDA approval difference has its biggest real-world impact.

IV Ketamine Costs

Per session: $400–$800 (self-pay)
Drug cost alone: Under $10 per dose — ketamine is a generic anesthetic, not a patented drug
6-session induction protocol: $2,400–$4,800
Ongoing monthly maintenance: $4,800–$9,600/year (assuming 1 session per month at $400–$800)

The gap between the $10 drug cost and the $400–$800 session price reflects clinic overhead: facility, staffing, monitoring, anesthesiology, and the clinical infrastructure required for safe administration.

Spravato Costs (Uninsured / Cash-Pay)

Drug retail cost: $882–$1,059 for the 56mg dose; $1,319–$1,663 for the 84mg dose (per Drugs.com and SingleCare)
Mandatory 2-hour REMS observation period: Adds $300–$700+ in facility and monitoring fees
Total per session (cash-pay): Approximately $1,050–$1,200 for cash-pay patients; $1,400–$2,000 as billed to insurance
Full 21-session protocol (uninsured): Approximately $22,000–$42,000+

Note: The wholesale acquisition cost (WAC) of Spravato is approximately $590 (56mg) and $885 (84mg), but this is not the price patients encounter. Retail and cash-pay prices are consistently higher.

The standard Spravato protocol (2x/week for 4 weeks, then tapering) involves more sessions than a typical IV ketamine induction, and the branded drug pricing is orders of magnitude higher than generic ketamine — making uninsured Spravato one of the most expensive psychiatric treatment courses available. First-month induction costs are especially steep, with medication costs alone potentially reaching $7,000–$13,000 at retail before savings programs.

Spravato Costs (With Insurance + Savings Programs)

For commercially insured patients who qualify, the picture changes radically:

J&J Spravato withMe Savings Program:

Medication copay reduced to $10 per treatment session for eligible commercially insured patients
Annual cap: $8,150 per year
Separate Observation Rebate Program: Covers monitoring/facility costs — eligible patients pay $0 after rebate for the observation portion
Combined, eligible insured patients may pay as little as $10 per session total
The withMe program is rebate-based — patients often pay upfront and submit for reimbursement within 365 days (checks arrive in 2–3 weeks)
Not available for Medicare, Medicaid, TRICARE, VA, or DoD patients. Observation rebate not valid in MA, MN, or RI
Enroll at Account.JNJwithMe.com or call 844-479-4846

Total out-of-pocket for a 21-session protocol (insured + withMe + observation rebate): Approximately $210–$1,050, depending on facility fee structure and rebate timing.

J&J Patient Assistance Foundation (jjpaf.org): Uninsured or underinsured patients earning ≤400% of the Federal Poverty Level can receive Spravato at no cost for up to one year. Patients who cannot afford the drug and don't have insurance should ask their clinic about this program before assuming Spravato is out of reach.

Insurance Coverage: The Starkest Contrast

Spravato: Broadly Covered

100% of 18 major commercial insurers cover Spravato for its FDA-approved indications
94.4% of plans require prior authorization — coverage is not automatic, but it is available
Typical prior authorization requirements:
- Formal TRD diagnosis
- 2+ failed adequate antidepressant trials (some plans require 3)
- Baseline depression severity scores documented
- Treatment must occur at a REMS-certified facility

Prior authorization takes time — typically 2–4 weeks — and requires documentation from your prescribing psychiatrist. It can be denied and appealed. But the fundamental coverage infrastructure exists.

IV Ketamine: Largely Uncovered for Depression

Only approximately 1.2% of commercial insurance plans clearly cover IV ketamine for depression
Coverage for pain management indications is more common, but psychiatric use remains outside almost all insurance formularies
The off-label status gives insurers clear grounds for denial, and nearly all use it

This coverage asymmetry is the single most financially consequential difference between the two treatments. A patient with commercial insurance who qualifies for Spravato can realistically access treatment for under $3,000 for a full protocol. The same patient paying self-pay for IV ketamine faces $2,400–$4,800 for induction alone — with no insurance to absorb any of it.

Side-by-Side: Who Should Consider Each Option

Consider Spravato if you:

Have a formal TRD diagnosis with 2+ documented failed antidepressant trials
Have commercial insurance (the coverage and savings program combination is powerful)
Can access a REMS-certified facility (most major psychiatric practices and some infusion centers)
Are comfortable with self-administered nasal spray and 2-hour in-office monitoring sessions
Qualify for the Janssen Patient Assistance Program (uninsured/low income)

Consider IV Ketamine if you:

Are uninsured or self-pay (lower upfront cost per session)
Don't meet the criteria for Spravato's indications
Have responded better to full racemic ketamine historically
Prefer or require IV administration (faster, more precise dosing)
Are treating a condition beyond TRD/MDD-SI (chronic pain, PTSD, OCD — where only ketamine clinics operate)
Want to avoid the REMS facility requirement and monitoring protocol

The honest answer for most patients:

If you have commercial insurance and a qualifying TRD diagnosis, pursue Spravato coverage first. The insurance landscape makes it dramatically more accessible financially. The efficacy data is comparable to IV ketamine, and the long-term SUSTAIN-3 data suggests durable benefit for many patients.

If you're self-pay, lack a qualifying diagnosis, or are treating something other than TRD or MDD-SI, IV ketamine at a qualified clinic is likely the more practical option — at $400–$800/session compared to $1,050–$2,000/session uninsured for Spravato.

Practical Access Considerations

Finding a Spravato provider: Because of REMS requirements, not every ketamine clinic is certified to administer Spravato. Many psychiatry practices are REMS-certified, while some infusion-focused ketamine clinics offer only IV. When searching, filter specifically for Spravato if that's your target.

The prior authorization timeline: Budget 2–6 weeks for Spravato prior authorization. Your psychiatrist will need to document your treatment history (failed antidepressants, diagnosis, severity scores). Starting this paperwork early avoids delays once you've decided to pursue it.

IV ketamine and superbills: While insurance rarely covers IV ketamine for depression outright, patients with PPO plans can submit superbills for out-of-network reimbursement. Clinics typically bill using CPT 96365 (IV infusion, initial, up to 1 hour) paired with J3490 (unclassified drugs). Reimbursement is not guaranteed — patients can realistically expect to recover 20–50% of billed costs depending on deductibles and the insurer's usual-and-customary rates, which are often well below billed charges for ketamine. Note: many clinics now omit J3490 from superbills because insurers reimburse almost nothing for the drug itself.

The Bottom Line

Both IV ketamine and Spravato have robust clinical evidence for treatment-resistant depression. The Mayo Clinic's 2025 meta-analysis found comparable efficacy. The choice between them, for most patients, comes down to practical factors — not just which works "better."

Spravato's FDA approval makes it insurable. For commercially insured TRD patients, that changes the financial calculus completely.
IV ketamine's off-label status means self-pay is almost always required for psychiatric use, but the drug cost is minimal and session pricing is lower uninsured.
The NNT data suggests esketamine has a stronger acute (24-hour) response, while IV ketamine's advantage holds better over 1–4 weeks.
Janssen's programs — both the withMe Savings Program and the Patient Assistance Program — dramatically reduce out-of-pocket Spravato costs for eligible patients, and are underutilized.

Neither treatment is a cure. Both typically require ongoing maintenance. And both work best when supported by psychotherapy and a comprehensive mental health treatment plan.

Browse Spravato-certified clinics → Browse IV ketamine clinics →

Sources

Kim JW et al. (Mayo Clinic). Comparative efficacy of IV ketamine vs. esketamine — systematic review and meta-analysis (8 studies, n=978). Therapeutic Advances in Psychopharmacology, 2025
Anand A et al. ELEKT-D: IV ketamine vs. ECT for TRD (N=403). NEJM, 2023
Morriss R et al. ESCAPE-TRD: esketamine vs. quetiapine augmentation (N=676). NEJM, 2023
Calder AJ et al. NNT meta-analysis for IV ketamine and esketamine in depression. Journal of Affective Disorders, 2024
Alvear M. Insurance coverage analysis of 18 major US commercial insurers (85.9M members). SSRN preprint, 2025

Clinical data cited in this article is based on published peer-reviewed trials and meta-analyses as referenced. Pricing data reflects 2026 retail prices from Drugs.com and SingleCare, published clinic rates, and J&J program documentation. Insurance coverage statistics reflect analysis of major commercial insurer formularies. This article is for informational purposes only and does not constitute medical or financial advice. Always consult a qualified healthcare provider before beginning any treatment program.